Abaloparatide

Drug Profile

Abaloparatide

Alternative Names: Abaloparatide TD; Abaloparatide-SC; BA 058; BA-058-SC; BA-058-TD; BIM-44058; ITM-058; PTHrP; Synthetic human parathyroid hormone 37-70 analogue - Ipsen

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator 3M Drug Delivery Systems; Biomeasure Inc; Ipsen
  • Developer Radius; Teijin Pharma
  • Class Calcium regulators; Osteoporosis therapies; Peptide hormones
  • Mechanism of Action Osteogenesis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Postmenopausal osteoporosis

Highest Development Phases

  • Preregistration Postmenopausal osteoporosis

Most Recent Events

  • 04 Nov 2016 Radius plans a bioequivalence study for abaloparatide transdermal micro-needle patch formulation
  • 18 Sep 2016 Additional efficacy data from the phase III ACTIVE trial in Postmenopausal osteoporosis released by Radius Health
  • 16 Aug 2016 Updated efficacy data from a phase III trial in Postmenopausal osteoporosis released by Radius Health
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top